Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 17 Ovarian Neoplasms 16 Fallopian Tube Neoplasms 12 Neoplasm Metastasis 10 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 7 Neoplasms 7 Endometrial Neoplasms 6 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neuroendocrine Tumors 3 Metastatic Castration-resistant Prostate Cancer 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Solid Tumors 2 Sarcoma 2 Recurrence 2 Pheochromocytoma 2 Paraganglioma 2 Osteosarcoma 2 Neuroblastoma 2 Multiple Myeloma 2 Medulloblastoma 2 Glioma 2 Glioblastoma 2 Ependymoma 2

Interventions

Cyclophosphamide 15 fludarabine 12 Mycophenolic Acid 10 Standard of Care 9 Whole-Body Irradiation 7 Tacrolimus 7 venetoclax 6 Specimen Handling 6 Sirolimus 6 Practice Guidelines as Topic 6 trametinib 5 Melphalan 5 fludarabine phosphate 4 Mesna 4 Magnetic Resonance Spectroscopy 4 Filgrastim 4 Biopsy 4 Behavior Therapy 4 Azacitidine 4 Thiotepa 3 Peripheral Blood Stem Cell Transplantation 3 GSK2636771 3 Educational Status 3 Crizotinib 3 Busulfan 3 thymoglobulin 2 talquetamab 2 ruxolitinib 2 palbociclib 2 osimertinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × olaparib × 90 days × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡